Future Vision II Acquisition Corp. (FVN)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Mar 31, 2025	Dec 31, 2024
Selling, General & Admin	0.37	0.21
Operating Expenses	0.37	0.21
Operating Income	-0.37	-0.21
Interest & Investment Income	0.02	0.01
Other Non Operating Income (Expenses)	1.5	0.89
Pretax Income	1.15	0.7
Net Income	1.15	0.7
Net Income to Common	1.15	0.7
Shares Outstanding (Basic)	5	3
Shares Outstanding (Diluted)	5	3
EBIT	-0.37	-0.21

Updated Mar 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q